Foresite Capital Management IV’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Foresite Capital Management IV’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-65,000	Closed	-$1.01M	–	15
2020 Q1	$1.01M	Buy	+65,000	New	+$1.02M	1.24%	9
2019 Q3	–	Sell	-63,922	Closed	-$866K	–	21
2019 Q2	$866K	Hold	63,922	–	–	0.24%	22
2019 Q1	$1.15M	Hold	63,922	–	–	0.41%	16
2018 Q4	$1.8M	Sell	63,922 -30,555	-32%	-$638K	0.82%	17
2018 Q3	$2.41M	Hold	94,477	–	–	0.79%	18
2018 Q2	$1.64M	Buy	+94,477	New	+$1.71M	0.56%	16

Other funds holding KNSA

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Foresite Capital Management IV's KNSA Position: Q2 2020 in Review

Foresite Capital Management IV sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2020, closing a stake of 65,000 shares — an estimated $1.01M sold.

Foresite Capital Management IV first reported a position in KNSA in Q2 2018 and held it in 6 quarters. The position peaked at $2.41M in Q3 2018. 96 funds tracked by Wall St. Rank hold KNSA as of Q2 2020.

Foresite Capital Management IV reported no remaining Kiniksa Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Foresite Capital Management IV sold 65,000 Kiniksa Pharmaceuticals shares in Q2 2020, an estimated $1.01M.
Foresite Capital Management IV first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 6 quarters.
Foresite Capital Management IV's Kiniksa Pharmaceuticals position peaked at $2.41M in Q3 2018.
96 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2020.

Based on Foresite Capital Management IV's 13F filing for Q2 2020, filed 13 Aug 2020.